News
- 17 September 2018
The 7 Deadly Sins of Audits and Inspections
Stuart Halasz, Associate Director, Clinical Quality Management, Merck & Co., Inc., focuses on “7 Deadly Sins” in Audits and Inspections – and thoughts on reducing their occurrence
- 14 September 2018
The Brexit Clock is Ticking, Are You Ready?
With Brexit only months away, CTA’s Charlie Abrines explains why the pharmaceutical industry should prepare for the worst
- 13 September 2018
The Keys to CRO Selection
Martin Bauer, Head of Clinical Research, provides insight on the challenges of partnering with CROs and vendors
- 12 September 2018
Clinical Trials in the US Midwest: Looking Back
As OCT & CTS Midwest gets underway, CTA pays tribute to previous articles written by authors from the US Midwest
- 11 September 2018
Annex 16 and Achieving QP Release for EU Clinical Trials: Adapting Operationally to Meet the Latest Requirements
Robert Bronstein, Dynavax Technologies, discusses Annex 16 and what every clinical supply chain manager needs to know to avoid potential QP release pitfalls
- 10 September 2018
EU Clinical Trial Regulation: The Long Path to Implementation
Surendra Gokhale & Claire Berry, Roche, discuss the journey, challenges and opportunities of the Clinical Trial Regulation
- 7 September 2018
Industry Viewpoints: Investigator-Initiated Studies – A Challenge for Supply with IMPs?
Peter Orosz, Head of Clinical Supply Chain Management & Oncology, Boehringer Ingelheim, addresses the challenges of investigator-initiated clinical trials
- 6 September 2018
Expert Insights: UK Drug Stockpiling Begins as CMOs Complain of Brexit Uncertainty
Fiona Barry, Associate Editor, PharmSource, assesses what impact the prospect of Brexit is having for CMOs
- 4 September 2018
Industry Viewpoints: Refining Your Outsourcing Strategy
Nadia Salem, Senior Director Medical Affairs, Leadiant Biosciences, explains to CTA’s Elizabeth Williams the keys to enhancing your outsourcing strategy
- 3 September 2018
Serialization of Prescription Drugs: Readiness from Development into Commercialization
Hector Tamburini, Exec. Director, Regulatory Affairs & CMC, Prometheus Laboratories, examines how the industry needs to comply with regulations concerning serialization
